Marinus Pharmaceuticals Names Dr. Rolando Gutíerrez-Esteinou as VP of Clinical Development and Pharmacovigilance
October 10 2018 - 7:30AM
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical
company dedicated to the development of innovative therapeutics to
treat epilepsy and neuropsychiatric disorders, announced the
appointment of Rolando Gutíerrez-Esteinou, M.D., as Vice President
of Clinical Development and Pharmacovigilance where he will
primarily be responsible for the medical leadership of our
postpartum depression (PPD) programs and drug safety.
“Dr. Gutíerrez-Esteinou is a welcome addition to
the management team at Marinus,” said Christopher Cashman, Chairman
and CEO of Marinus Pharmaceuticals. “His decades of experience in
the clinical development of neuropsychiatric and central nervous
system (CNS) therapies will be invaluable as Marinus completes its
Phase 2 trials in PPD and develops its later-stage development
strategy in depression.”
Dr. Gutíerrez-Esteinou was previously Executive
Director and Global Clinical Leader, Psychiatry, at Takeda
Pharmaceuticals, and Vice President and Global Therapeutic Area
Head at Covance Clinical Development Services. He has also held
positions at Prostrakan, Inc.; Bristol-Myers Squibb; Novartis
Pharmaceuticals; and the Janssen Research Foundation. He holds an
M.D. from the National Autonomous University of Mexico Medical
School, Mexico City, and was a resident and research fellow at
Harvard Medical School.
“I feel fortunate to join Marinus at this
exciting and busy time,” said Dr. Rolando Gutíerrez-Esteinou.
“Ganaxolone represents true innovation in a field that had only
seen variations of the same anti-depressant mechanisms of action
for 20 years. With its novel mechanism of action and convenient
dose forms, ganaxolone has the potential to provide benefits to
these patients.”
Ganaxolone is designed to provide anti-seizure
activity by calming the brain and restoring its electrical balance.
Ganaxolone’s method of action is different from existing epilepsy
and anti-depressant medications, binding to unique GABAA receptors.
In clinical trials to date, ganaxolone has shown to be safe and
well-tolerated, and effective in reducing seizures and anxiety in
various patient populations. Its functional similarity to
reproductive hormones also suggests it may help correct the
hormonal imbalance seen in women suffering from postpartum
depression.
About Marinus
PharmaceuticalsMarinus Pharmaceuticals, Inc. is a
biopharmaceutical company dedicated to the development of
ganaxolone, which offers a new mechanism of action, demonstrated
efficacy and safety, and convenient dosing to improve the lives of
patients suffering from epilepsy and neuropsychiatric disorders.
Ganaxolone is a positive allosteric modulator of GABAA that acts on
a well-characterized target in the brain known to have
anti-seizure, anti-depressant and anti-anxiety effects. Ganaxolone
is being developed in three different dose forms (IV, capsule and
liquid) intended to maximize therapeutic reach to adult and
pediatric patient populations in both acute and chronic care
settings. Marinus has initiated the first ever pivotal study
in children with CDKL5 deficiency disorder, a rare form of
epilepsy, and is currently conducting studies in patients with
postpartum depression and refractory status epilepticus. For more
information visit www.marinuspharma.com. Please follow us on
Twitter: @MarinusPharma.
Forward-Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Marinus, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Words such as “may”, “will”, “expect”, “anticipate”,
“estimate”, “intend”, “believe”, and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking
statements. Examples of forward-looking statements contained
in this press release include, among others, statements regarding
our interpretation of preclinical studies, development plans for
our product candidate, including the development of dose forms, the
clinical trial testing schedule and milestones, the ability to
complete enrollment in our clinical trials, interpretation of
scientific basis for ganaxolone use, timing for availability and
release of data, the safety, potential efficacy and therapeutic
potential of our product candidate and our expectation regarding
the sufficiency of our working capital. Forward-looking statements
in this release involve substantial risks and uncertainties that
could cause our clinical development programs, future results,
performance or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Such risks
and uncertainties include, among others, the uncertainties inherent
in the conduct of future clinical trials, the timing of the
clinical trials, enrollment in clinical trials, availability of
data from ongoing clinical trials, expectations for regulatory
approvals, the attainment of clinical trial results that will be
supportive of regulatory approvals, and other matters, including
the development of formulations of ganaxolone, and the availability
or potential availability of alternative products or treatments for
conditions targeted by the Company that could affect the
availability or commercial potential of our drug candidates.
Marinus undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties that could cause actual results to differ from
those expressed in these forward-looking statements, as well as
risks relating to the business of the Company in general, see
filings Marinus has made with the Securities and Exchange
Commission.
CONTACT:Lisa M. CaperelliExecutive Director,
Investor & Strategic RelationsMarinus Pharmaceuticals,
Inc.484-801-4674lcaperelli@marinuspharma.com
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Apr 2023 to Apr 2024